Regulatory Briefs: FDA Meetings On Cancer Tests, Glaucoma Devices; DeLauro Questions Device Reclassifications
This article was originally published in The Gray Sheet
Executive Summary
An FDA advisory panel will discuss PMAs for two molecular diagnostics for colorectal cancer screening in March. A February workshop will address clinical trial design for minimally invasive glaucoma devices. Rep. DeLauro speaks out about FDA device reclassifications. More regulatory briefs.